格隆汇8月4日丨联环药业(600513.SH)公布，公司控股子公司新乡常乐制药有限责任公司(称"常乐制药") 于近日收到国家药品监督管理局核准签发的关于盐酸林可霉素注射液《药品补充申请批准通知书》，批 准常乐制药本品通过仿制药质量和疗效一致性评价。盐酸林可霉素注射液(规格：2ml:0.6g)属林可酰胺 类抗生素，临床适用于敏感菌所致的呼吸道感染、皮肤软组织感染及骨关节感染等疾病。 盐酸林可霉素注射液通过一致性评价，有利于扩大该药品的市场份额，提升市场竞争力，上述《药品补 充申请批准通知书》的取得预计不会对公司近期经营业绩产生重大影响。 ...

Group 1 - The core point of the article is that Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection [1] - In 2025, Changle Pharmaceutical obtained a total of 2 production licenses [1] - The research and development investment for the consistency evaluation has reached approximately 2.328 million yuan [1] Group 2 - In 2024, the domestic sales revenue of Lincomycin Hydrochloride Injection in sample hospitals amounted to 10.8176 million yuan [1]

Market Overview - On August 4, the state-owned enterprise reform sector rose by 0.37% compared to the previous trading day, with Dongjie Intelligent leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in State-Owned Enterprise Reform Sector - Dongjie Intelligent (300486) closed at 66.91, with a gain of 19.99% and a trading volume of 487,500 shares, amounting to a transaction value of 803 million yuan [1] - Feile Audio (600651) closed at 6.12, up 10.07%, with a trading volume of 1,221,200 shares and a transaction value of 724 million yuan [1] - Great Wall Electric (600192) closed at 10.86, gaining 10.03%, with a trading volume of 437,300 shares and a transaction value of 465 million yuan [1] - Other notable gainers include Guojijinggong (002046), Changcheng Military Industry (601606), and Construction Industry (002265), all showing gains around 10% [1] Top Losers in the Market - Shili Monitoring (300528) saw a decline of 11.33%, closing at 18.93, with a trading volume of 723,800 shares and a transaction value of 1.411 billion yuan [2] - Zhonghua Equipment (600579) fell by 9.18%, closing at 9.10, with a trading volume of 572,500 shares and a transaction value of 527 million yuan [2] - Shanghai Film (601595) decreased by 7.87%, closing at 36.39, with a trading volume of 352,400 shares and a transaction value of 1.299 billion yuan [2] Capital Flow Analysis - On the same day, the state-owned enterprise reform sector experienced a net inflow of 400 million yuan from institutional investors, while retail investors saw a net inflow of 1.119 billion yuan [2] - However, speculative funds recorded a net outflow of 1.518 billion yuan [2] Individual Stock Capital Flow - Construction Industry (002265) had a net inflow of 716 million yuan from institutional investors, while it faced a net outflow of 342 million yuan from speculative funds [3] - Changcheng Military Industry (601606) saw a net inflow of 547 million yuan from institutional investors, with a net outflow of 292 million yuan from speculative funds [3] - Aerospace Electronics (600879) recorded a net inflow of 459 million yuan from institutional investors, but faced a net outflow of 233 million yuan from speculative funds [3]

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant increase in stock price and trading volume, indicating positive market sentiment despite a decline in net profit [1]. Financial Performance - As of Q1 2025, the company reported total revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1]. - The net profit attributable to shareholders was 23.06 million yuan, a decrease of 29.15% year-on-year [1]. - The non-recurring net profit was 22.15 million yuan, down 27.95% year-on-year [1]. - The current ratio is 1.173, the quick ratio is 0.786, and the debt-to-asset ratio stands at 50.71% [1]. Market Activity - On August 4, 2025, the stock closed at 20.82 yuan, up 9.98%, with a turnover rate of 21.76% and a trading volume of 621,200 hands, amounting to a transaction value of 1.203 billion yuan [1]. - The net inflow of main funds was 160 million yuan, accounting for 13.28% of the transaction value, with large orders contributing 132 million yuan [1]. Company Background - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was established in 2000 and is located in Yangzhou, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 2.854 billion yuan and a paid-in capital of 40 million yuan [1][2]. - The legal representative of the company is Qian Zhenhua [1]. Investment and Intellectual Property - The company has made investments in 13 enterprises and participated in 5,000 bidding projects [2]. - It holds 46 trademark registrations and 240 patent applications, along with 559 administrative licenses [2].

Core Viewpoint - On August 4, Lianhuan Pharmaceutical experienced a 9.98% increase in stock price, reaching 20.82 CNY per share, with a trading volume of 1.163 billion CNY and a turnover rate of 21.09%, resulting in a total market capitalization of 5.943 billion CNY [1] Company Overview - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various forms of medications including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Nifedipine. The company boasts a high-end R&D team of nearly 200 members and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025 (January to March), Lianhuan Pharmaceutical reported a revenue of 628 million CNY, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million CNY, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]

风险提示：股市有风险，投资需谨慎。 截至13时46分，联环药业涨停，最新价20.82元，封板资金达2.51亿元，成交额11.64亿元，换手率 21.12%。公司所属化学制药行业，总市值59.43亿元。8月1日创新药概念板块表现强势，联环药业与汉 商集团双双涨停，显示市场对该领域的关注度较高。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced a stock price increase of 6.5% on August 4, reaching 20.16 yuan per share, with a trading volume of 904 million yuan and a turnover rate of 16.63%, resulting in a total market capitalization of 5.755 billion yuan [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Felodipine. The company boasts a high-end R&D team of nearly 200 people and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025, Jiangsu Lianhuan Pharmaceutical reported an operating income of 628 million yuan, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]

Market Overview - The Shanghai Composite Index fell by 0.94% this week, with six industries experiencing gains, led by the pharmaceutical and biotechnology sector, which rose by 2.95% [1] - The coal and non-ferrous metals industries saw the largest declines, with drops of 4.67% and 4.62% respectively [1] Fund Flow Analysis - A total of 211.86 billion yuan was net withdrawn from the two markets this week, with only the banking sector seeing a net inflow of 4.33 billion yuan [1] - The non-ferrous metals industry had the highest net outflow, totaling 25.99 billion yuan, followed by the computer industry with a net outflow of 20.45 billion yuan [1][2] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector had a net outflow of 4.68 billion yuan this week, despite a price increase of 2.95% [3] - Out of 474 stocks in this sector, 323 stocks rose, with notable gainers including Nanjing New Pharmaceutical (up 78.01%), Lide Man (up 46.45%), and Chenxin Pharmaceutical (up 40.88%) [3] - The sector also saw 36 stocks with net outflows exceeding 100 million yuan, with WuXi AppTec leading at 1.98 billion yuan [3][4] Top Gainers and Losers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: up 29.52% with a net inflow of 1.01 billion yuan - Anke Bio: up 25.93% with a net inflow of 0.36 billion yuan - Lianhuan Pharmaceutical: up 15.99% with a net inflow of 0.34 billion yuan [3] - The top losers included: - WuXi AppTec: down 4.64% with a net outflow of 1.98 billion yuan - Borui Pharmaceutical: down 0.14% with a net outflow of 0.71 billion yuan - Kanglong Chemical: up 0.33% with a net outflow of 0.51 billion yuan [4]

Core Insights - The avian influenza concept sector saw an increase of 1.62%, ranking fourth among concept sectors in terms of growth, with 20 stocks rising, including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Yongshun Biological, which rose by 7.49%, 7.31%, and 6.32% respectively [1] - The sector experienced a net inflow of 938 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 30 million yuan, led by Zhongsheng Pharmaceutical with a net inflow of 533 million yuan [1] Sector Performance - The top-performing concept sectors included: - Animal vaccines: +2.22% - DRG/DIP: +1.87% - BC batteries: +1.71% - Avian influenza: +1.62% - Medical waste treatment: +1.61% [1] Fund Flow Analysis - Leading stocks in terms of fund inflow ratios included: - Lianhuan Pharmaceutical: 21.80% - Zhongsheng Pharmaceutical: 15.06% - Taiji Group: 9.94% [2] - The top stocks by main fund flow included: - Zhongsheng Pharmaceutical: 532.84 million yuan - Lianhuan Pharmaceutical: 278.91 million yuan - Taiji Group: 97.84 million yuan [2][3]